TAO Synergies TAOX
NASDAQ TAOX
$4.14 +0.13 (+3.10%)
As of: Sep 9, 2026 · 1:19 PM EDT

TAO Synergies (TAOX) Total Non-Current Liabilities (2021 - 2026)

TAO Synergies' (TAOX) quarterly Total Non-Current Liabilities came in at $1.0 million in Q2 2026, down 3.22% on a YoY basis from $1.1 million in Q2 2025, and down 6.98% quarter-over-quarter from $1.1 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Total Non-Current Liabilities for 6 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Non-Current Liabilities fell 3.22% year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.0 million (down 3.22% YoY), and the FY2025 full-year result was $1.8 million, down 61.87% from the prior year.
  • Total Non-Current Liabilities fell to $1.0 million in Q2 2026 per TAOX's latest filing, from $1.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $9.4 million in Q2 2024 and bottomed at $1.0 million in Q2 2026.
  • Historically, Total Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $2.3 million in 2023.
  • The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 349.0% in 2024, then plunged 88.5% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $1.7 million in 2022, then jumped by 162.4% to $4.4 million in 2023, then grew by 8.24% to $4.8 million in 2024, then slumped by 61.87% to $1.8 million in 2025, then slumped by 42.91% to $1.0 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.0 million, $1.1 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn 378.37 Mn
10 TAO Synergies 30.90 Mn 30.90 Mn - 1.04 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.04 Mn
Mar 31, 2026 1.12 Mn
Dec 31, 2025 1.82 Mn
Sep 30, 2025 1.04 Mn
Jun 30, 2025 1.08 Mn
Mar 31, 2025 2.63 Mn
Dec 31, 2024 4.78 Mn
Sep 30, 2024 3.59 Mn
Jun 30, 2024 9.35 Mn
Mar 31, 2024 6.38 Mn
Dec 31, 2023 4.42 Mn
Sep 30, 2023 2.27 Mn
Jun 30, 2023 3.90 Mn
Mar 31, 2023 1.42 Mn
Dec 31, 2022 1.68 Mn
Dec 31, 2021 -7.91 Mn